Organon Ends Livial Program In The U.S.
This article was originally published in The Pink Sheet Daily
Executive Summary
Oraganon will drop all efforts to market its hormone therapy Livial (tibolone) in the United States following a June 1 "not approvable" letter. The company was seeking an indication for treatment of menopausal symptoms